Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by MrMugsyon Aug 02, 2021 3:51pm
218 Views
Post# 33640320

RE:$1.60 per share in perceived value

RE:$1.60 per share in perceived value
Amigo11 wrote: Strip out cash of $1.80 per share or thereabouts and there is less perceived future value in the stock than the cash component.Without significant indebtedness it is clear that "the market" believes that this is a real long shot.I am willing to pay current pricing for a warrant on the analgesic industry that doesn't expire.I don't know when it turns but .....


At 65M shares, I see the cash at $1.10

Looking at the minimum likely intake with larger geography partnerships and I see an additional $2.98 CAD in 2022.  Then remove the cash we spend over 2021-2022 and that's likely around $50M ($0.77 per share). 

You quickly see what we likely have in the bank going into 2023.  If share only trade at 3x cash (like it's doing now) ... you quickly see where the price could be.

Then in 2022, the NASDAQ will help us value our shares much higher than 3x cash, with everything that's happening ... hard to think the shares will only be at 3x cash.  I'm also thinking a partner or partners will be forking the bills for P3 and we'll be creating new entities during that time.

That ... my friend ... is why I started buying again below 40 cents and why I continue to buy today.  H2S is highly unknown and people don't really get it yet.  That will come quickly ... when it comes.

All in my opinion though. 

Happy "whatever" holiday it is today folks !!!!!

<< Previous
Bullboard Posts
Next >>

USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse